Article
Multidisciplinary Sciences
Liming Tian, Xuemei Li, Huiling Lai, Tingting Sun, Xiaohui Li, Linxiang Wu, Chuling Wu, Shuzhong Yao, Yufeng Ren, Shasha He, Guofen Yang
Summary: Ovarian cancer has a high mortality rate and requires early diagnosis and new drugs. This study investigated the effectiveness of SLC11A2 as a therapeutic target and marker for ovarian cancer. Expression data, biological function validation, and test efficacy validation of SLC11A2 were conducted. Results showed that high expression of SLC11A2 was associated with shorter survival rates and increased cancer migration. Serum SLC11A2 may improve the detection rate of ovarian cancer.
SCIENTIFIC REPORTS
(2023)
Review
Pharmacology & Pharmacy
Munther Alomari
Summary: TRIM21 is involved in innate immunity, systemic lupus erythematosus, Sjogren's syndrome, and cancer proliferation. It is shown to affect major cancer-promoting proteins and signaling pathways in the presence of various carcinogenesis effectors. TRIM21 may enhance cancer proliferation or induce the degradation of cancer-triggering proteins, highlighting its potential as a novel cancer therapeutic target.
PHARMACOLOGICAL RESEARCH
(2021)
Review
Oncology
Upasana Ray, Christopher L. Pathoulas, Prabhu Thirusangu, James W. Purcell, Nagarajan Kannan, Viji Shridhar
Summary: Abundant fibrotic stroma is a common feature in solid tumors, and targeting the tumor stroma, including the overexpressed LRRC15 protein, has become a promising therapeutic strategy. Effective LRRC15-targeted therapy may improve outcomes for patients with LRRC15-positive tumors, offering personalized clinical benefits and predictive biomarkers for preclinical assessment.
Review
Cell Biology
Yunqing Chen, Hongyan Fan, Shijun Wang, Guanmin Tang, Changlin Zhai, Liang Shen
Summary: Ischemia-reperfusion (I/R) injury is a major cause of cell death and organ damage in various pathologies, and current treatment methods are limited. Ferroptosis, a newly discovered type of regulated cell death characterized by iron overload and lipid peroxidation accumulation, has been found to have a close association with I/R injury, making it a potential new therapeutic target. This review summarizes the current status of ferroptosis and explores its relationship with I/R injury, as well as potential treatment strategies.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Haoya Xu, Ruoyao Zou, Feifei Li, Jiyu Liu, Nannan Luan, Shengke Wang, Liancheng Zhu
Summary: This study identified six MRPs related to HE4 in ovarian cancer, with MRPL15 being highly expressed and associated with poor prognosis. MRPL15 plays a role in ovarian cancer through pathways such as the cell cycle, DNA repair, and mTOR 1 signaling. High expression of MRPL15 in ovarian cancer may be associated with its amplification and hypomethylation, and it is correlated with the proliferation of CD8(+) T cells and dendritic cells in C3 ovarian cancer as well as the expression of TGF beta R1 and IDO1.
Article
Pathology
Weijian Zhou, Jie Mei, Dingyi Gu, Junying Xu, Runjie Wang, Huiyu Wang, Chaoying Liu
Summary: Despite the rapid development of novel adjuvant and neoadjuvant chemotherapeutic drugs in recent years, advanced ovarian cancer still lacks effective treatment strategies and remains one of the main causes of death among women. Wnt5a protein expression has been observed to be significantly upregulated in ovarian cancer and associated with poor prognosis. Downregulating Wnt5a levels effectively suppresses ovarian cancer cell migration and invasion abilities, suggesting it as a promising novel therapeutic target for future treatments.
PATHOLOGY RESEARCH AND PRACTICE
(2021)
Review
Oncology
Lanyu Li, Cheng Qiu, Min Hou, Xinyu Wang, Changzhen Huang, Jialin Zou, Tianyi Liu, Jinfeng Qu
Summary: Ovarian cancer, as one of the deadliest malignancies, requires more effective treatment options beyond traditional methods. The potential connection between ferroptosis and ovarian cancer has raised interest in exploring new therapeutic approaches. Further research is needed to understand the role of ferroptosis in ovarian cancer treatment and to identify potential pathways for intervention.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Jing Shen, Mengru Xie, Yuxin Xu, Qilan Qian, Teng Qiu, Wen Shi, Dexu Ren, Jing Ji, Jinling Huang
Summary: Ubiquitin specific proteinase 28 (USP28) is highly expressed in ovarian cancer (OV) samples and elevated USP28 levels are associated with poor prognosis. USP28 abnormal expression is linked to the activation of the I3-catenin signaling pathway and it is a transcriptional target gene of the I3-catenin/YAP1/TBX5 complex. Genetic ablation or pharmacological inhibition of USP28 impairs the proliferation ability of OV cells. These findings suggest that USP28 may serve as a therapeutic target for ovarian cancer.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Review
Pharmacology & Pharmacy
Fan Zeng, Yunping Lan, Ning Wang, Xiaobo Huang, Qiao Zhou, Yi Wang
Summary: Bladder cancer, the most frequent type of urinary system cancer, has a poor prognosis due to high metastasis rates and multidrug resistance. The development of novel therapies targeting bladder cancer cell death is urgently needed. Ferroptosis, a novel cell death type with strong antitumor potential, has been investigated by many groups for its potential in bladder cancer treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Cassie Liu, Carter J. Barger, Adam R. Karpf
Summary: Ovarian cancer is a lethal disease with a low 10-year survival rate worldwide, and the aberrant expression and activation of FOXM1 is a key molecular alteration in this cancer. FOXM1 is a master transcriptional regulator that promotes critical oncogenic phenotypes in ovarian cancer, making it a potential target for cancer therapy.
Review
Endocrinology & Metabolism
Xi-Ding Yang, Yong-Yu Yang
Summary: This review summarizes the role and regulatory mechanisms of ferroptosis in diabetes and its complications, as well as the inhibitors of ferroptosis in diabetes and diabetic complications. Understanding the regulation of ferroptosis and developing drugs targeting ferroptosis may provide new treatment strategies for patients with diabetes.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Oncology
Lingnan Kong, Famei Xu, Yukuan Yao, Zhihui Gao, Peng Tian, Shichao Zhuang, Di Wu, Tangyue Li, Yanling Cai, Jing Li
Summary: This study used a proximity barcoding assay to analyze the surface proteins on single extracellular vesicles (EVs). They found that the CDCP1+ EVs subcluster was significantly increased in the ascites of ovarian cancer patients, and the level of CDCP1 was also significantly elevated. The group with high CDCP1 expression had significantly lower overall survival and disease-free survival rates. EVs-derived CDCP1 was identified as a biomarker for early response in ovarian cancer ascites.
FRONTIERS IN ONCOLOGY
(2023)
Article
Immunology
Yumei Fan, Bing Liu, Fei Chen, Zhiyuan Song, Bihui Han, Yanxiu Meng, Jiajie Hou, Pengxiu Cao, Yanzhong Chang, Ke Tan
Summary: The study found that high expression of hepcidin in lung cancer patients is associated with unfavorable prognosis and immune cell infiltration levels. Hepcidin may affect prognosis in lung cancer patients by regulating immune cell infiltration.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Adrian Dumitru, Elena-Codruta Dobrica, Adina Croitoru, Sanda Maria Cretoiu, Bogdan Severus Gaspar
Summary: Ovarian cancer is a highly aggressive and deadly gynecological malignancy, with immunomodulation playing an important role in cancer treatment. However, current data is insufficient to identify patients who respond to immunotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Cell Biology
Joselyn Padilla, Jiyoung Lee
Summary: BACH1 is a transcription factor highly expressed in tumors, promoting invasion and metastasis of cancer cells and presenting a poor outcome for cancer patients. Recent studies have identified novel functional roles of BACH1 in the regulation of metabolic pathways in cancer cells.
Article
Oncology
Konstantinos Votanopoulos, Steven Forsythe, Hemamylammal Sivakumar, Andrea Mazzocchi, Julio Aleman, Lance Miller, Edward Levine, Pierre Triozzi, Aleksander Skardal
ANNALS OF SURGICAL ONCOLOGY
(2020)
Article
Cell Biology
Emanuel J. Novais, Victoria A. Tran, Jingya Miao, Katie Slaver, Andrew Sinensky, Nathaniel A. Dyment, Sankar Addya, Flora Szeri, Koen van de Wetering, Irving M. Shapiro, Makarand V. Risbud
Article
Biology
Leilei Zhong, Lutian Yao, Robert J. Tower, Yulong Wei, Zhen Miao, Jihwan Park, Rojesh Shrestha, Luqiang Wang, Wei Yu, Nicholas Holdreith, Xiaobin Huang, Yejia Zhang, Wei Tong, Yanqing Gong, Jaimo Ahn, Katalin Susztak, Nathanial Dyment, Mingyao Li, Fanxin Long, Chider Chen, Patrick Seale, Ling Qin
Article
Oncology
William H. Gmeiner, Lance D. Miller, Jeff W. Chou, Anthony Dominijanni, Lysette Mutkus, Frank Marini, Jimmy Ruiz, Travis Dotson, Karl W. Thomas, Graham Parks, Christina R. Bellinger
Article
Biophysics
Ryan J. Leiphart, Snehal S. Shetye, Stephanie N. Weiss, Nathaniel A. Dyment, Louis J. Soslowsky
JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME
(2020)
Article
Oncology
Mara De Martino, Camille Daviaud, Julie M. Diamond, Jeffrey Kraynak, Amandine Alard, Silvia C. Formenti, Lance D. Miller, Sandra Demaria, Claire Vanpouille-Box
Summary: Increased Tregs were found in mice tumors treated with focal radiotherapy and TGF beta blockade, mediated by upregulation of activin A. In vitro, activin A secretion was increased post-irradiation, and dual blockade of activin A and TGF beta was required to decrease intratumoral Tregs in vivo. Targeting activin A may reduce Treg-mediated immunosuppression, supporting the development of tumor-specific memory responses in irradiated breast cancer when combined with immune checkpoint inhibitors.
CANCER IMMUNOLOGY RESEARCH
(2021)
Article
Engineering, Biomedical
Brian D. Cosgrove, Claudia Loebel, Tristan P. Driscoll, Tonia K. Tsinman, Eric N. Dai, Su-Jin Heo, Nathaniel A. Dyment, Jason A. Burdick, Robert L. Mauck
Summary: The degree of nuclear envelope wrinkling can predict mechanotransduction state in mesenchymal progenitor cells and highlights the differential mechanisms of nuclear envelope stress generation operative in 2D and 3D microenvironmental contexts.
Article
Medicine, Research & Experimental
Wei Yu, Leilei Zhong, Lutian Yao, Yulong Wei, Tao Gui, Ziqing Li, Hyunsoo Kim, Nicholas Holdreith, Xi Jiang, Wei Tong, Nathaniel Dyment, X. Sherry Liu, Shuying Yang, Yongwon Choi, Jaimo Ahn, Ling Qin
Summary: Our study identified marrow adipogenic lineage precursors (MALPs) as a critical player in controlling bone remodeling during normal bone metabolism and pathological bone loss in a RANKL-dependent fashion.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Genetics & Heredity
Qianqian Song, Jing Su, Lance D. Miller, Wei Zhang
Summary: In gene expression profiling studies, specifically in single-cell RNA sequencing analyses, accurately identifying and clustering co-expressed genes is essential for understanding cell identity and function. Existing methods for single-cell data often fail to accurately identify co-expressed genes, but the scLM algorithm tailored for single-cell data proves to be effective in detecting biologically significant gene clusters and can cluster multiple single-cell datasets simultaneously. Results from simulation and experimental data show that scLM outperforms existing methods and provides novel biological insights for mechanism discovery and understanding complex biosystems like cancer.
GENOMICS PROTEOMICS & BIOINFORMATICS
(2021)
Article
Oncology
Steven D. Forsythe, Richard A. Erali, Shyama Sasikumar, Preston Laney, Ethan Shelkey, Ralph D'Agostino, Lance D. Miller, Perry Shen, Edward A. Levine, Shay Soker, Konstantinos Votanopoulos
Summary: Immunotherapy demonstrated measurable efficacy in appendiceal cancer organoids, especially in high-grade appendiceal cancer patients. Information derived from immunocompetent organoids may be useful in selecting patients for clinical trial enrollment in rare diseases.
CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, General & Internal
Debargha Basuli, Rohan Umesh Parekh, Acacia White, Abdullah Thayyil, Srinivas Sriramula
Summary: Despite available therapies, hypertensive kidney disease remains a significant cause of chronic kidney disease, leading to increased morbidity and mortality rates. This study reveals the importance of the B1 receptor in the development of inflammation and fibrosis in hypertensive kidney disease, providing potential targets for therapeutic interventions.
FRONTIERS IN MEDICINE
(2022)
Article
Oncology
Pierre L. Triozzi, Elizabeth R. Stirling, Qianqian Song, Brian Westwood, Mitra Kooshki, M. Elizabeth Forbes, Beth C. Holbrook, Katherine L. Cook, Martha A. Alexander-Miller, Lance D. Miller, Wei Zhang, David R. Soto-Pantoja
Summary: In this study, the bioenergetics of circulating immune cells and the metabolomic profiles of plasma were compared in melanoma patients treated with anti-PD-1 therapy. It was found that patients who responded to the therapy had higher respiratory capacity and glycolytic activity compared to nonresponders. Metabolomic analysis also revealed differences in metabolic signatures between responder and nonresponder patient samples. The study suggests that blood bioenergetics and metabolomics can be used as predictive biomarkers for patient response to immune checkpoint inhibitor therapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Rebecca Anderson, Lance D. Miller, Scott Isom, Jeff W. Chou, Kristin M. Pladna, Nathaniel J. Schramm, Leslie R. Ellis, Dianna S. Howard, Rupali R. Bhave, Megan Manuel, Sarah Dralle, Susan Lyerly, Bayard L. Powell, Timothy S. Pardee
Summary: This study reports the results of a phase II study that combines devimistat with cytarabine and mitoxantrone in patients with relapsed or refractory AML. The study found that inhibition of mitochondrial fission or autophagy sensitizes AML cells to devimistat. Additionally, an age-related decline in mitochondrial quality and autophagy may be associated with response to devimistat.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Margaret R. Smith, Yuezhu Wang, Ralph D'Agostino, Yin Liu, Jimmy Ruiz, Thomas Lycan, George Oliver, Lance D. Miller, Umit Topaloglu, Jireh Pinkney, Mohammed N. Abdulhaleem, Michael D. Chan, Michael Farris, Jing Su, Kathryn F. Mileham, Fei Xing
Summary: Different therapy options are used for NSCLC based on tumor stage and genetic mutations. However, biomarkers to guide treatment selection are limited. A study collected clinical and sequencing data from 524 NSCLC patients to examine the association between mutation profiles and treatment response. Mutation composite scores (MCS) were generated for different treatments, and MCS showed superior predictive power compared to other biomarkers in immune therapy-treated patients.
NPJ PRECISION ONCOLOGY
(2023)
Article
Gastroenterology & Hepatology
Fariha Ilyas, Hassam Ali, Pratik Patel, Shiza Sarfraz, Debargha Basuli, Alexa Giammarino, Sanjaya Kumar Satapathy
Summary: We observed an increasing trend in NAFLD-related mortality in the United States from 1999 to 2022. There were significant differences in mortality rates between sexes, racial groups, and age groups. Females showed a steeper increase than males, with white individuals having the highest mortality rate. Older populations had a higher mortality rate compared to younger age groups.
HEPATOLOGY COMMUNICATIONS
(2023)